Analysts Anticipate Bruker Co. (BRKR) Will Announce Quarterly Sales of $418.40 Million
Brokerages predict that Bruker Co. (NASDAQ:BRKR) will announce sales of $418.40 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Bruker’s earnings, with estimates ranging from $403.40 million to $433.40 million. Bruker posted sales of $384.90 million during the same quarter last year, which suggests a positive year-over-year growth rate of 8.7%. The firm is expected to report its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Bruker will report full-year sales of $418.40 million for the current financial year, with estimates ranging from $1.86 billion to $1.89 billion. For the next year, analysts anticipate that the business will post sales of $1.95 billion per share, with estimates ranging from $1.91 billion to $1.98 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Bruker.
Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.02. Bruker had a net margin of 4.45% and a return on equity of 26.58%. The firm had revenue of $530.50 million for the quarter, compared to analyst estimates of $506.74 million. During the same quarter last year, the business posted $0.46 earnings per share. The company’s quarterly revenue was up 12.8% on a year-over-year basis.
Shares of Bruker (BRKR) traded up $0.25 during trading on Thursday, reaching $29.90. 376,382 shares of the company’s stock were exchanged, compared to its average volume of 560,323. Bruker has a 1 year low of $21.83 and a 1 year high of $36.53. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. The firm has a market capitalization of $4,651.33, a price-to-earnings ratio of 61.02, a P/E/G ratio of 1.99 and a beta of 1.16.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 23rd. Investors of record on Tuesday, March 6th will be issued a $0.04 dividend. The ex-dividend date of this dividend is Monday, March 5th. This represents a $0.16 annualized dividend and a yield of 0.54%. Bruker’s payout ratio is 32.65%.
A number of hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its holdings in Bruker by 5.7% in the fourth quarter. Acadian Asset Management LLC now owns 5,229,258 shares of the medical research company’s stock valued at $179,467,000 after buying an additional 280,245 shares during the period. BlackRock Inc. lifted its holdings in Bruker by 7.1% in the fourth quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock valued at $177,566,000 after buying an additional 341,389 shares during the period. State Street Corp lifted its holdings in Bruker by 0.5% in the second quarter. State Street Corp now owns 1,407,941 shares of the medical research company’s stock valued at $40,605,000 after buying an additional 7,356 shares during the period. Geode Capital Management LLC lifted its holdings in Bruker by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 1,294,131 shares of the medical research company’s stock valued at $44,414,000 after buying an additional 31,742 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Bruker by 1.3% in the third quarter. Dimensional Fund Advisors LP now owns 921,431 shares of the medical research company’s stock valued at $27,412,000 after buying an additional 11,466 shares during the period. Institutional investors and hedge funds own 65.89% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/analysts-anticipate-bruker-co-brkr-will-announce-quarterly-sales-of-418-40-million/1907702.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.